Status:
TERMINATED
Aripiprazole Treatment of the Prodrome
Lead Sponsor:
Northwell Health
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Prodromal Schizophrenia
Prodromal Psychosis
Eligibility:
All Genders
13-22 years
Phase:
NA
Brief Summary
The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole. This drug has been approved for treating symptoms associated with schizophrenia and is associated with fewe...
Detailed Description
During the 12-week study, eligible patients are seen 7-9 times by research raters and psychiatrists. These visits include side effect monitoring, scheduled medication increases, and ratings designed t...
Eligibility Criteria
Inclusion
- You are between the ages of 13 and 22.
- You are English-speaking.
- You have a diagnosed psychotic disorder, including: schizophrenia, schizophreniform disorder, schizoaffective disorder, or other psychotic disorder
- OR -
- You are experiencing one or more pre-psychotic symptoms like unusual thoughts, suspiciousness, or unusual perceptual experiences.
- You meet additional RAP criteria assessed during screening and interview.
Exclusion
- You have a diagnosis of bipolar disorder or major depression with psychotic features.
- You have a history of neurological, neuroendocrine, or other medical conditions known to affect the brain.
- You have past or current substance dependence.
- You are currently taking Aripiprazole.
- You have taken Aripiprazole in the past.
- You are currently taking and responding well to another medication.
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00169949
Start Date
January 1 2004
End Date
May 1 2006
Last Update
September 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
RAP Program, Dept. of Psychiatry Research, The Zucker Hillside Hospital
Glen Oaks, New York, United States, 11004